Biotechnology

Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity

January 16, 2024 8:00 AM

ALLEN, TX / ACCESSWIRE / January 16, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. has partnered with The Khalpey AI Lab to improve organ recovery, longevity, and the science of aging by combining drug development with artificial intelligence. This collaboration is a significant step in the biotechnology industry, aiming to reshape the complex biology of aging and organ regeneration. The partnership aims to...

Read more

Hyris Fulfils Its Integration Into Ulisse Biomed to Give Birth to a New International Group Ready to Make Its Mark in the Global Biotech Market

January 15, 2024 2:00 AM

Following the first official announcement at the beginning of December last year, Hyris completed the transfer of its shares into Ulisse Biomed via a reverse take-over transaction. The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market. LONDON, ENGLAND / ACCESSWIRE / January 15, 2024 / A new international biotech group was...

Read more

BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis

January 12, 2024 2:20 AM

Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ACCESSWIRE / January 12, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer...

Read more

CB Scientific, Inc. 2023 Year in Review

January 11, 2024 8:30 AM

The following press release is no longer available.

Read more

AppYea Enters Commercial Phase with First Deliveries of AppySleep to Customers in the U.S.

January 10, 2024 9:30 AM

AppySleep now available for purchase online Plans to sell the product in stores as part of planned second phase of rollout GAN YAVNE, ISRAEL / ACCESSWIRE / January 10, 2024 / AppYea, Inc. (OTCQB:APYP), developer of an innovative and accurate wearable monitoring solution to treat sleep apnea and snoring, today announced it has formally entered its commercial phase with the first shipments of AppySleep to customers in the U.S. AppySleep is...

Read more

AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS(R) for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

January 9, 2024 8:15 AM

PREVYMIS® now approved in the U.S. and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R‑]) EMA approval triggers a €15 Million Milestone payment to AiCuris and AiCuris is eligible for further milestone payments and royalties on future net sales Obtained funds will further boost the clinical development of AiCuris' product candidate...

Read more

Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued

January 9, 2024 8:00 AM

Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an independent research report by Marble Arch Research The report can be viewed on the...

Read more

FluoGuide Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

January 8, 2024 6:00 AM

KØBENHAVN, DENMARK / ACCESSWIRE / January 8, 2024 / FluoGuide A/S (STO:FLUO) Strong phase II data on FG001 in three indications: brain, head & neck, lung cancers Assessing potential of photothermal therapy in aggressive brain cancer Clinical trial to be used for registration of FG001 in fluorescent guided surgery of aggressive brain cancer expected to start in 2025 Phase II trial in head & neck cancer, which offers a range of opportunities with...

Read more

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 8, 2024 2:20 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also...

Read more

Radiance Therapeutics to Present at the Biotech Showcase 2024 in San Francisco

January 5, 2024 7:50 AM

EMERYVILLE, CA / ACCESSWIRE / January 5, 2024 / Radiance Therapeutics, an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller, MSc. MD, will be presenting the company at Biotech Showcase™ 2024 in San Francisco, CA. This year, registered attendees can view Radiance Therapeutics' presentation live and also access a recorded version. Radiance Therapeutics will be presenting on Tuesday, January 9,...

Read more

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

January 4, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management plans to participate in the 2024 Dermatology Summit on January 7, 2024 as well as in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024 in San...

Read more

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

January 4, 2024 9:05 AM

Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®: Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug delivery; and Reduced side effects. KELONA, BC / ACCESSWIRE / January 4, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive final results...

Read more

Seraxis' Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes

January 4, 2024 9:00 AM

GMP-compliant manufacturing puts SR-02 on track to be industry's second clinical-stage stem cell derived pancreatic islet transplant program. The third-party auditor's FDA six-system approach yielded no critical nor major observations of Seraxis' quality system for the production of GMP-grade organs from pancreas-derived stem cells. Dr. William Rust, CEO, will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 on...

Read more

BioInvent Announces 2024 Strategic Priorities and Anticipated Milestones

January 4, 2024 8:45 AM

Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024 Well-financed with 1358 SEK million (~USD 132M), as of September 30, 2023 LUND, SE / ACCESSWIRE / January 4, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

Read more

MRES: M2MMA Gears Up for a Landmark Year in 2024

January 2, 2024 9:35 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / January 2, 2024 / Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates with its M2MMA division: As M2MMA embarks on 2024, the...

Read more

NovAccess Global Announces $10.7 Million Financing

January 2, 2024 8:00 AM

Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced it entered into a securities purchase agreement with an affiliate of Sumner Global LLC ("Sumner") for a total financing of $10.7 million. Pursuant to the agreement, Sumner agreed to...

Read more

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 20, 2023 4:05 PM

- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it successfully...

Read more

Canyon Labs Announces Senior Leadership Changes

December 20, 2023 9:00 AM

Medical Device and Pharmaceutical Veterans Join Leadership of Canyon Labs to Bring Best-in-Class Customer Experience. SALT LAKE CITY, UT / ACCESSWIRE / December 20, 2023 / Canyon Labs announces the appointment of Sarah Ptach as President and Wendy Mach as Senior Director of Technical Services to further enhance leadership expertise in the pharmaceutical and medical device service industries. These new leadership roles represent a commitment to...

Read more

Cenna Announces Appointment of David H. Crean to Board of Directors

December 19, 2023 9:00 PM

Cardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer's Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego's 500 Most Influential People for the Last Four Years LA JOLLA, CA / ACCESSWIRE / December 19, 2023 / Cenna Biosciences today announced the appointment of David H. Crean to the Cenna Board of Directors effective...

Read more

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

December 19, 2023 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum. A quorum consists of one third of the outstanding shares of our common stock (present in person (including virtually) or...

Read more